Calithera Biosciences, Inc. (NASDAQ:CALA) Expected to Post Earnings of -$0.20 Per Share

Wall Street brokerages expect that Calithera Biosciences, Inc. (NASDAQ:CALA) will announce ($0.20) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Calithera Biosciences’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.11). Calithera Biosciences posted earnings per share of ($0.32) during the same quarter last year, which suggests a positive year-over-year growth rate of 37.5%. The firm is expected to issue its next quarterly earnings results on Tuesday, March 15th.

On average, analysts expect that Calithera Biosciences will report full year earnings of ($0.82) per share for the current financial year, with EPS estimates ranging from ($0.90) to ($0.73). For the next financial year, analysts forecast that the firm will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.79) to ($0.18). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Calithera Biosciences.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Monday, November 8th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.08. During the same period last year, the firm posted ($0.32) EPS.

Several brokerages recently weighed in on CALA. HC Wainwright lowered Calithera Biosciences from a “buy” rating to a “neutral” rating in a report on Monday, November 8th. William Blair downgraded Calithera Biosciences from an “outperform” rating to a “market perform” rating in a report on Friday, November 5th. Finally, Zacks Investment Research cut Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, October 11th.

In other Calithera Biosciences news, CEO Susan Molineaux bought 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 10th. The shares were acquired at an average cost of $0.85 per share, for a total transaction of $85,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Keith Orford sold 51,810 shares of the business’s stock in a transaction that occurred on Tuesday, November 9th. The stock was sold at an average price of $0.84, for a total transaction of $43,520.40. The disclosure for this sale can be found here. 11.60% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CALA. JPMorgan Chase & Co. raised its holdings in shares of Calithera Biosciences by 19.0% in the 1st quarter. JPMorgan Chase & Co. now owns 104,941 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 16,756 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Calithera Biosciences by 20.9% during the first quarter. Geode Capital Management LLC now owns 1,151,234 shares of the biotechnology company’s stock valued at $2,785,000 after acquiring an additional 199,317 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Calithera Biosciences by 75.3% during the first quarter. Renaissance Technologies LLC now owns 560,855 shares of the biotechnology company’s stock valued at $1,357,000 after acquiring an additional 240,955 shares during the period. Barclays PLC raised its holdings in shares of Calithera Biosciences by 44.4% during the first quarter. Barclays PLC now owns 55,367 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 17,026 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Calithera Biosciences during the first quarter valued at approximately $31,000. Institutional investors and hedge funds own 73.87% of the company’s stock.

Shares of NASDAQ CALA traded up $0.01 during midday trading on Friday, reaching $0.89. 605,662 shares of the company’s stock were exchanged, compared to its average volume of 1,309,700. Calithera Biosciences has a 52-week low of $0.81 and a 52-week high of $6.19. The stock has a market capitalization of $66.53 million, a PE ratio of -0.94 and a beta of 1.57. The business’s fifty day moving average price is $1.74 and its two-hundred day moving average price is $2.01.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.

Further Reading: How to invest in blue-chip stocks

Get a free copy of the Zacks research report on Calithera Biosciences (CALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.